UK-based Quell Therapeutics Ltd is to out-licence a candidate cell therapy for inflammatory bowel disease to AstraZeneca Plc following the achievement of a research milestone. Further details of the research goal were not disclosed. The two companies have been collaborating since 2023 in the development of engineered T-regulatory (Treg) cell therapies for two immune-mediated disease indications. Inflammatory bowel disease is one indication and Type 1 diabetes is the other. The achievement of the milestone will trigger a payment to Quell of $10 million.